Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors

Jesper B. Andersen, Bart Spee, Boris R. Blechacz, Itzhak Avital, Mina Komuta, Andrew Barbour, Elizabeth A. Conner, Matthew C. Gillen, Tania Roskams, Lewis Rowland Roberts, Valentina M. Factor, Snorri S. Thorgeirsson

Research output: Contribution to journalArticle

246 Citations (Scopus)

Abstract

Background & Aims: Cholangiocarcinoma is a heterogeneous disease with a poor outcome that accounts for 5%-10% of primary liver cancers. We characterized its genomic and genetic features and associated these with patient responses to therapy. Methods: We profiled the transcriptomes from 104 surgically resected cholangiocarcinoma samples collected from patients in Australia, Europe, and the United States; epithelial and stromal compartments from 23 tumors were laser capture microdissected. We analyzed mutations in KRAS, epidermal growth factor receptor (EGFR), and BRAF in samples from 69 tumors. Changes in gene expression were validated by immunoblotting and immunohistochemistry; integrative genomics combined data from the patients with data from 7 human cholangiocarcinoma cell lines, which were then exposed to trastuzumab and lapatinib. Results: Patients were classified into 2 subclasses, based on 5-year survival rate (72% vs 30%; χ 2 = 11.61; P <.0007), time to recurrence (13.7 vs 22.7 months; P <.001), and the absence or presence of KRAS mutations (24.6%), respectively. Class comparison identified 4 survival subgroups (SGIIV; χ 2 = 8.34; P <.03); SGIII was characterized by genes associated with proteasomal activity and the worst prognosis. The tumor epithelium was defined by deregulation of the HER2 network and frequent overexpression of EGFR, the hepatocyte growth factor receptor (MET), pRPS6, and Ki67, whereas stroma was enriched in inflammatory cytokines. Lapatinib, an inhibitor of HER2 and EGFR, was more effective in inhibiting growth of cholangiocarcinoma cell lines than trastuzumab. Conclusions: We provide insight into the pathogenesis of cholangiocarcinoma and identify previously unrecognized subclasses of patients, based on KRAS mutations and increased levels of EGFR and HER2 signaling, who might benefit from dual-target tyrosine kinase inhibitors. The group of patients with the worst prognosis was characterized by transcriptional enrichment of genes that regulate proteasome activity, indicating new therapeutic targets.

Original languageEnglish (US)
JournalGastroenterology
Volume142
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Cholangiocarcinoma
Protein-Tyrosine Kinases
Epidermal Growth Factor Receptor
Mutation
Therapeutics
Proto-Oncogene Proteins c-met
Cell Line
Neoplasms
Proteasome Endopeptidase Complex
Liver Neoplasms
Genomics
Transcriptome
Immunoblotting
Genes
Lasers
Survival Rate
Epithelium
Immunohistochemistry
Cytokines
Gene Expression

Keywords

  • CCA
  • Gene Expression
  • Genetic Analysis
  • Hepatic

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Andersen, J. B., Spee, B., Blechacz, B. R., Avital, I., Komuta, M., Barbour, A., ... Thorgeirsson, S. S. (2012). Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology, 142(4). https://doi.org/10.1053/j.gastro.2011.12.005

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. / Andersen, Jesper B.; Spee, Bart; Blechacz, Boris R.; Avital, Itzhak; Komuta, Mina; Barbour, Andrew; Conner, Elizabeth A.; Gillen, Matthew C.; Roskams, Tania; Roberts, Lewis Rowland; Factor, Valentina M.; Thorgeirsson, Snorri S.

In: Gastroenterology, Vol. 142, No. 4, 04.2012.

Research output: Contribution to journalArticle

Andersen, JB, Spee, B, Blechacz, BR, Avital, I, Komuta, M, Barbour, A, Conner, EA, Gillen, MC, Roskams, T, Roberts, LR, Factor, VM & Thorgeirsson, SS 2012, 'Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors', Gastroenterology, vol. 142, no. 4. https://doi.org/10.1053/j.gastro.2011.12.005
Andersen, Jesper B. ; Spee, Bart ; Blechacz, Boris R. ; Avital, Itzhak ; Komuta, Mina ; Barbour, Andrew ; Conner, Elizabeth A. ; Gillen, Matthew C. ; Roskams, Tania ; Roberts, Lewis Rowland ; Factor, Valentina M. ; Thorgeirsson, Snorri S. / Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. In: Gastroenterology. 2012 ; Vol. 142, No. 4.
@article{235218b624274f19b9fe30feb8fb13bc,
title = "Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors",
abstract = "Background & Aims: Cholangiocarcinoma is a heterogeneous disease with a poor outcome that accounts for 5{\%}-10{\%} of primary liver cancers. We characterized its genomic and genetic features and associated these with patient responses to therapy. Methods: We profiled the transcriptomes from 104 surgically resected cholangiocarcinoma samples collected from patients in Australia, Europe, and the United States; epithelial and stromal compartments from 23 tumors were laser capture microdissected. We analyzed mutations in KRAS, epidermal growth factor receptor (EGFR), and BRAF in samples from 69 tumors. Changes in gene expression were validated by immunoblotting and immunohistochemistry; integrative genomics combined data from the patients with data from 7 human cholangiocarcinoma cell lines, which were then exposed to trastuzumab and lapatinib. Results: Patients were classified into 2 subclasses, based on 5-year survival rate (72{\%} vs 30{\%}; χ 2 = 11.61; P <.0007), time to recurrence (13.7 vs 22.7 months; P <.001), and the absence or presence of KRAS mutations (24.6{\%}), respectively. Class comparison identified 4 survival subgroups (SGIIV; χ 2 = 8.34; P <.03); SGIII was characterized by genes associated with proteasomal activity and the worst prognosis. The tumor epithelium was defined by deregulation of the HER2 network and frequent overexpression of EGFR, the hepatocyte growth factor receptor (MET), pRPS6, and Ki67, whereas stroma was enriched in inflammatory cytokines. Lapatinib, an inhibitor of HER2 and EGFR, was more effective in inhibiting growth of cholangiocarcinoma cell lines than trastuzumab. Conclusions: We provide insight into the pathogenesis of cholangiocarcinoma and identify previously unrecognized subclasses of patients, based on KRAS mutations and increased levels of EGFR and HER2 signaling, who might benefit from dual-target tyrosine kinase inhibitors. The group of patients with the worst prognosis was characterized by transcriptional enrichment of genes that regulate proteasome activity, indicating new therapeutic targets.",
keywords = "CCA, Gene Expression, Genetic Analysis, Hepatic",
author = "Andersen, {Jesper B.} and Bart Spee and Blechacz, {Boris R.} and Itzhak Avital and Mina Komuta and Andrew Barbour and Conner, {Elizabeth A.} and Gillen, {Matthew C.} and Tania Roskams and Roberts, {Lewis Rowland} and Factor, {Valentina M.} and Thorgeirsson, {Snorri S.}",
year = "2012",
month = "4",
doi = "10.1053/j.gastro.2011.12.005",
language = "English (US)",
volume = "142",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors

AU - Andersen, Jesper B.

AU - Spee, Bart

AU - Blechacz, Boris R.

AU - Avital, Itzhak

AU - Komuta, Mina

AU - Barbour, Andrew

AU - Conner, Elizabeth A.

AU - Gillen, Matthew C.

AU - Roskams, Tania

AU - Roberts, Lewis Rowland

AU - Factor, Valentina M.

AU - Thorgeirsson, Snorri S.

PY - 2012/4

Y1 - 2012/4

N2 - Background & Aims: Cholangiocarcinoma is a heterogeneous disease with a poor outcome that accounts for 5%-10% of primary liver cancers. We characterized its genomic and genetic features and associated these with patient responses to therapy. Methods: We profiled the transcriptomes from 104 surgically resected cholangiocarcinoma samples collected from patients in Australia, Europe, and the United States; epithelial and stromal compartments from 23 tumors were laser capture microdissected. We analyzed mutations in KRAS, epidermal growth factor receptor (EGFR), and BRAF in samples from 69 tumors. Changes in gene expression were validated by immunoblotting and immunohistochemistry; integrative genomics combined data from the patients with data from 7 human cholangiocarcinoma cell lines, which were then exposed to trastuzumab and lapatinib. Results: Patients were classified into 2 subclasses, based on 5-year survival rate (72% vs 30%; χ 2 = 11.61; P <.0007), time to recurrence (13.7 vs 22.7 months; P <.001), and the absence or presence of KRAS mutations (24.6%), respectively. Class comparison identified 4 survival subgroups (SGIIV; χ 2 = 8.34; P <.03); SGIII was characterized by genes associated with proteasomal activity and the worst prognosis. The tumor epithelium was defined by deregulation of the HER2 network and frequent overexpression of EGFR, the hepatocyte growth factor receptor (MET), pRPS6, and Ki67, whereas stroma was enriched in inflammatory cytokines. Lapatinib, an inhibitor of HER2 and EGFR, was more effective in inhibiting growth of cholangiocarcinoma cell lines than trastuzumab. Conclusions: We provide insight into the pathogenesis of cholangiocarcinoma and identify previously unrecognized subclasses of patients, based on KRAS mutations and increased levels of EGFR and HER2 signaling, who might benefit from dual-target tyrosine kinase inhibitors. The group of patients with the worst prognosis was characterized by transcriptional enrichment of genes that regulate proteasome activity, indicating new therapeutic targets.

AB - Background & Aims: Cholangiocarcinoma is a heterogeneous disease with a poor outcome that accounts for 5%-10% of primary liver cancers. We characterized its genomic and genetic features and associated these with patient responses to therapy. Methods: We profiled the transcriptomes from 104 surgically resected cholangiocarcinoma samples collected from patients in Australia, Europe, and the United States; epithelial and stromal compartments from 23 tumors were laser capture microdissected. We analyzed mutations in KRAS, epidermal growth factor receptor (EGFR), and BRAF in samples from 69 tumors. Changes in gene expression were validated by immunoblotting and immunohistochemistry; integrative genomics combined data from the patients with data from 7 human cholangiocarcinoma cell lines, which were then exposed to trastuzumab and lapatinib. Results: Patients were classified into 2 subclasses, based on 5-year survival rate (72% vs 30%; χ 2 = 11.61; P <.0007), time to recurrence (13.7 vs 22.7 months; P <.001), and the absence or presence of KRAS mutations (24.6%), respectively. Class comparison identified 4 survival subgroups (SGIIV; χ 2 = 8.34; P <.03); SGIII was characterized by genes associated with proteasomal activity and the worst prognosis. The tumor epithelium was defined by deregulation of the HER2 network and frequent overexpression of EGFR, the hepatocyte growth factor receptor (MET), pRPS6, and Ki67, whereas stroma was enriched in inflammatory cytokines. Lapatinib, an inhibitor of HER2 and EGFR, was more effective in inhibiting growth of cholangiocarcinoma cell lines than trastuzumab. Conclusions: We provide insight into the pathogenesis of cholangiocarcinoma and identify previously unrecognized subclasses of patients, based on KRAS mutations and increased levels of EGFR and HER2 signaling, who might benefit from dual-target tyrosine kinase inhibitors. The group of patients with the worst prognosis was characterized by transcriptional enrichment of genes that regulate proteasome activity, indicating new therapeutic targets.

KW - CCA

KW - Gene Expression

KW - Genetic Analysis

KW - Hepatic

UR - http://www.scopus.com/inward/record.url?scp=84859441690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859441690&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2011.12.005

DO - 10.1053/j.gastro.2011.12.005

M3 - Article

C2 - 22178589

AN - SCOPUS:84859441690

VL - 142

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 4

ER -